| Followers | 47 |
| Posts | 23580 |
| Boards Moderated | 0 |
| Alias Born | 09/16/2012 |
Tuesday, March 02, 2021 1:45:27 PM
Help me understand what LL is saying here? She seems to be saying she could do what NWBO does but that's not going to work. Then she says what does works is personalized. Very confusing:
"And we give it. We either license it out or start your own little startup. Here at Stanford, it’s a very start-up environment. It depends on your goals. If your goal is to have a startup and then have a pharmaceutical company buy you out or get an IPO, you could do that. We could do the same thing Northwest Bio, Tocagen, Selbach, or any of these companies that have already done trials do.
But at the end of the day, it doesn’t really cure GBM unless there’s something a little bit broader. I guess in my heart of hearts, I think what’s going to cure the disease is going to be personalized. It’s going to be something that comes from the person or the tumor itself and I’m not sure how that can be patented other than the idea and the process by which that’s done."
-LL
"And we give it. We either license it out or start your own little startup. Here at Stanford, it’s a very start-up environment. It depends on your goals. If your goal is to have a startup and then have a pharmaceutical company buy you out or get an IPO, you could do that. We could do the same thing Northwest Bio, Tocagen, Selbach, or any of these companies that have already done trials do.
But at the end of the day, it doesn’t really cure GBM unless there’s something a little bit broader. I guess in my heart of hearts, I think what’s going to cure the disease is going to be personalized. It’s going to be something that comes from the person or the tumor itself and I’m not sure how that can be patented other than the idea and the process by which that’s done."
-LL
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
